

Subject index

Volume 47 (2000)

Acyclovir (ACV); Anti-HIV activity; Anti-HSV activity; Human macrophages; (R)PMPA 47, 149

Acyclovir resistant; Pathogenesis; Genital herpes; Animal models 47, 159

Adenovirus; Antiviral; ddC; Pneumonia model in mouse 47, 79

Adipogenesis; HIV; Protease inhibitors; Lipolysis; Lipodystrophy 47, 121

AG7088; Human rhinovirus; Pleconaril; Protease inhibitors; Capsid binding agents 47, 217

Animal models; Pathogenesis; Acyclovir resistant; Genital herpes 47, 159

Antibodies; Monoclonal antibodies; Antiviral; Immune globulin; Therapy; Prophylaxis 47, 57

Antifolate; Cytomegalovirus; Thymidylate synthase; ZD1694; Ganciclovir 47, 111

Anti-HIV activity; Acyclovir (ACV); Anti-HSV activity; Human macrophages; (R)PMPA 47, 149

Anti-HSV activity; Acyclovir (ACV); Anti-HIV activity; Human macrophages; (R)PMPA 47, 149

Antiretroviral treatment; HIV; Plasma infectivity; Plasma viral load 47, 189

Antiviral; Adenovirus; ddC; Pneumonia model in mouse 47, 79

Antiviral; Antibodies; Monoclonal antibodies; Immune globulin; Therapy; Prophylaxis 47, 57

Antiviral; Cidofovir; Cowpox virus; Intranasal treatment 47, 171

Antiviral; Cytomegalovirus; CHPMPC; Guinea pig; Immune compromised 47, 103

Antiviral therapy; Protease inhibitor; Mutations; Protease gene; Resistance; HIV 47, 179

Anti virus; CMV promoter; Zinc; DTPA; Metallothionein 47, 207

Capsid binding agents; Human rhinovirus; AG7088; Pleconaril; Protease inhibitors 47, 217

Cell culture infectious dose; RSV infections; NMSO3 47, 41

CHPMPC; Cytomegalovirus; Antiviral; Guinea pig; Immune compromised 47, 103

Cidofovir; Antiviral; Cowpox virus; Intranasal treatment 47, 171

CMV promoter; Anti virus; Zinc; DTPA; Metallothionein 47, 207

Cowpox virus; Antiviral; Cidofovir; Intranasal treatment 47, 171

Cytomegalovirus; CHPMPC; Antiviral; Guinea pig; Immune compromised 47, 103

Cytomegalovirus; Thymidylate synthase; Antifolate; ZD1694; Ganciclovir 47, 111

ddC; Adenovirus; Antiviral; Pneumonia model in mouse 47, 79

DTPA; CMV promoter; Anti virus; Zinc; Metallothionein 47, 207

E6AP; HPV; ELISA 47, 199

ELISA; HPV; E6AP 47, 199

- Ganciclovir**; Cytomegalovirus; Thymidylate synthase; Antifolate; ZD1694 47, 111
- Genital herpes**; Pathogenesis; Acyclovir resistant; Animal models 47, 159
- Glycosylation**; Retinoic acid; Herpes simplex virus 47, 29
- Guinea pig**; Cytomegalovirus; CHPMPC; Antiviral; Immune compromised 47, 103
- Herpes simplex virus**; Retinoic acid; Glycosylation 47, 29
- Histoculture**; Nuclear import inhibitor; Lymphoid tissue; Reverse transcriptase 47, 89
- HIV**; Plasma infectivity; Plasma viral load; Antiretroviral treatment 47, 189
- HIV**; Protease inhibitor; Antiviral therapy; Mutations; Protease gene; Resistance 47, 179
- HIV**; Protease inhibitors; Adipogenesis; Lipolysis; Lipodystrophy 47, 121
- HPV**; E6AP; ELISA 47, 199
- Human macrophages**; Acyclovir (ACV); Anti-HIV activity; Anti-HSV activity; (R)PMPA 47, 149
- Human papillomavirus**; *Larrea tridentata*; Plant lignan 47, 19
- Human rhinovirus**; AG7088; Pleconaril; Protease inhibitors; Capsid binding agents 47, 217
- IFN administration route**; Murine IFN- β ; Mouse hepatitis virus 47, 131
- Immune compromised**; Cytomegalovirus; CHPMPC; Antiviral; Guinea pig 47, 103
- Immune globulin**; Antibodies; Monoclonal antibodies; Antiviral; Therapy; Prophylaxis 47, 57
- Influenza virus**; Neuraminidase inhibitors; Resistance to neuraminidase inhibitors 47, 1
- Integrase inhibitors**; Retroviruses; Resistance; Structure of integrases 47, 139
- Intranasal treatment**; Antiviral; Cidofovir; Cowpox virus 47, 171
- Larrea tridentata***; Plant lignan; Human papillomavirus 47, 19
- β -L-AZTTP**; WT HIV-1 RT; M184V HIV-1 RT, Chain termination 47, 97
- Lipodystrophy**; HIV; Protease inhibitors; Adipogenesis; Lipolysis 47, 121
- Lipolysis**; HIV; Protease inhibitors; Adipogenesis; Lipodystrophy 47, 121
- Lymphoid tissue**; Nuclear import inhibitor; Histoculture; Reverse transcriptase 47, 89
- Metallothionein**; CMV promoter; Anti virus; Zinc; DTPA 47, 207
- Monoclonal antibodies**; Antibodies; Antiviral; Immune globulin; Therapy; Prophylaxis 47, 57
- Mouse hepatitis virus**; Murine IFN- β ; IFN administration route 47, 131
- Murine IFN- β** ; Mouse hepatitis virus; IFN administration route 47, 131
- Mutations**; Protease inhibitor; Antiviral therapy; Protease gene; Resistance; HIV 47, 179
- M184V HIV-1 RT, Chain termination**; β -L-AZTTP; WT HIV-1 RT 47, 97
- Neuraminidase inhibitors**; Influenza virus; Resistance to neuraminidase inhibitors 47, 1
- NMSO3**; Cell culture infectious dose; RSV infections 47, 41
- Nuclear import inhibitor**; Lymphoid tissue; Histoculture; Reverse transcriptase 47, 89
- Pathogenesis**; Acyclovir resistant; Genital herpes; Animal models 47, 159
- Plant lignan**; *Larrea tridentata*; Human papillomavirus 47, 19
- Plasma infectivity**; HIV; Plasma viral load; Antiretroviral treatment 47, 189
- Plasma viral load**; HIV; Plasma infectivity; Antiretroviral treatment 47, 189
- Pleconaril**; Human rhinovirus; AG7088; Protease inhibitors; Capsid binding agents 47, 217
- Pneumonia model in mouse**; Adenovirus; Antiviral; ddC 47, 79
- Prophylaxis**; Antibodies; Monoclonal antibodies; Antiviral; Immune globulin; Therapy 47, 57
- Protease gene**; Protease inhibitor; Antiviral therapy; Mutations; Resistance; HIV 47, 179
- Protease inhibitor**; Antiviral therapy; Mutations; Protease gene; Resistance; HIV 47, 179

Protease inhibitors; HIV; Adipogenesis; Lipolysis; Lipodystrophy 47, 121

Protease inhibitors; Human rhinovirus; AG7088; Pleconaril; Capsid binding agents 47, 217

Resistance; Protease inhibitor; Antiviral therapy; Mutations; Protease gene; HIV 47, 179

Resistance; Retroviruses; Integrase inhibitors; Structure of integrases 47, 139

Resistance to neuraminidase inhibitors; Influenza virus; Neuraminidase inhibitors 47, 1

Retinoic acid; Herpes simplex virus; Glycosylation 47, 29

Retroviruses; Integrase inhibitors; Resistance; Structure of integrases 47, 139

Reverse transcriptase; Nuclear import inhibitor; Lymphoid tissue; Histoculture 47, 89

(R)PMPA; Acyclovir (ACV); Anti-HIV activity; Anti-HSV activity; Human macrophages 47, 149

RSV infections; Cell culture infectious dose; NMSO3 47, 41

Structure of integrases; Retroviruses; Integrase inhibitors; Resistance 47, 139

Therapy; Antibodies; Monoclonal antibodies; Antiviral; Immune globulin; Prophylaxis 47, 57

Thymidylate synthase; Cytomegalovirus; Antifolate; ZD1694; Ganciclovir 47, 111

WT HIV-1 RT; β -L-AZTTP; M184V HIV-1 RT, Chain termination 47, 97

ZD1694; Cytomegalovirus; Thymidylate synthase; Antifolate; Ganciclovir 47, 111

Zinc; CMV promoter; Anti virus; DTPA; Metallothionein 47, 207